The unique complexity of the CYP3A4 upstream region suggests a nongenetic explanation of its expression variability

Related Experiment Video

Updated: Jun 16, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Huan Qiu1, Marianne Mathäs, Sebastian Nestler

  • 1Department of Pharmacology, Universitätsmedizin, Johannes Gutenberg University, Mainz, Germany.

Pharmacogenetics and Genomics
|February 12, 2010
PubMed
Abstract

Insights

Intraindividual variability in CYP3A4 drug metabolism, impacting many medications, may stem from its complex regulatory region, not just gene variants. This complexity enhances CYP3A4 inducibility by specific ligands.

Area of Science:

  • Evolutionary biology
  • Pharmacogenomics
  • Molecular biology

Background:

  • CYP3A4 enzyme activity varies significantly between individuals, affecting the efficacy and safety of approximately 50% of modern drugs.
  • Genetic variations account for only a small portion of this observed inter-individual variability in CYP3A4 expression.

Purpose of the Study:

  • To investigate the evolutionary history of CYP3A4 transcriptional regulation.
  • To understand the role of nuclear receptors, specifically PXR and CAR (xenobiotic sensors), in shaping CYP3A4 gene expression patterns.

Main Methods:

  • Comparative analysis of CYP3A gene regulatory regions across different species, focusing on placental mammals and primates.
  • Identification and characterization of conserved and novel regulatory elements (ER6, XREM, CLEM, DR4) responsive to nuclear receptors.

Main Results:

  • The ancestral CYP3A regulatory scheme involving ER6, XREM, and CLEM elements is uniquely retained in human CYP3A4, while other CYP3A genes have lost these elements to varying degrees.
  • Primate evolution of CYP3A4 involved an increase in regulatory elements responsive to PXR and CAR, enhancing its inducibility.
  • Specific regulatory elements, like the CAR-responsive DR4 site in CYP3A5, show differential receptor binding compared to CYP3A4.

Conclusions:

  • The high intra-individual variability in human CYP3A4 expression is likely driven by the intricate complexity of its upstream regulatory region.
  • This unique regulatory architecture confers a particular sensitivity to endogenous and exogenous ligands of PXR and CAR, rather than solely relying on gene variants.

More Related Videos

An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations10:17

An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations

Published on: November 3, 2010

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...